Benitec Biopharma Inc.BNTCNASDAQ
LOADING
|||
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | 37.98% |
| Q2 2025 | -38.21% |
| Q1 2025 | 17.90% |
| Q4 2024 | 41.48% |
| Q3 2024 | 2.08% |
| Q2 2024 | 36.87% |
| Q1 2024 | -49.71% |
| Q4 2023 | 15.20% |
| Q3 2023 | 39.01% |
| Q2 2023 | 0.60% |
| Q1 2023 | -15.79% |
| Q4 2022 | 41.39% |
| Q3 2022 | -16.25% |
| Q2 2022 | 46.29% |
| Q1 2022 | -30.99% |
| Q4 2021 | 13.17% |
| Q3 2021 | 19.83% |
| Q2 2021 | -15.88% |
| Q1 2021 | 136.13% |
| Q4 2020 | 50.90% |
| Q3 2020 | -14.57% |
| Q2 2020 | 12.55% |
| Q1 2020 | 34.39% |
| Q4 2019 | 41.61% |
| Q3 2019 | -66.51% |
| Q2 2019 | 8.97% |
| Q1 2019 | -25.89% |
| Q4 2018 | 162.44% |
| Q3 2018 | -55.13% |
| Q2 2018 | 13.92% |
| Q1 2018 | -20.42% |
| Q4 2017 | 32.78% |
| Q3 2017 | -13.58% |
| Q2 2017 | 9.57% |
| Q1 2017 | 21.31% |
| Q4 2016 | -49.97% |
| Q3 2016 | 34.85% |
| Q2 2016 | -44.48% |
| Q1 2016 | 51.98% |
| Q4 2015 | -60.28% |